Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ORIC Stock Forecast 2026-2027
$10.38
Current Price
$1.16B
Market Cap
Buy 14
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ORIC Price Targets
+140.8%
To High Target of $25.00
+111.9%
To Median Target of $22.00
+44.5%
To Low Target of $15.00
ORIC Price Momentum
+16.8%
1 Week Change
-17.6%
1 Month Change
+140.8%
1 Year Change
+26.9%
Year-to-Date Change
-30.5%
From 52W High of $14.93
+166.5%
From 52W Low of $3.90
📊 TOP ANALYST CALLS
Did ORIC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ORIC Pharmaceuticals is one of their latest high-conviction picks.
Latest ORIC Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, ORIC has a bullish consensus with a median price target of $22.00 (ranging from $15.00 to $25.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $10.38, the median forecast implies a 111.9% upside. This outlook is supported by 14 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 140.8% upside. Conversely, the most conservative target is provided by Matthew Biegler at Oppenheimer, suggesting a 44.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ORIC Analyst Ratings
14
Buy
1
Hold
0
Sell
ORIC Price Target Range
Low
$15.00
Average
$22.00
High
$25.00
Current: $10.38
Latest ORIC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ORIC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Apr 1, 2026 | Wedbush | David Nierengarten | Outperform | Maintains | $17.00 |
| Mar 13, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Feb 24, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $17.00 |
| Feb 24, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $25.00 |
| Feb 24, 2026 | Wedbush | David Nierengarten | Outperform | Reiterates | $20.00 |
| Jan 13, 2026 | Wedbush | David Nierengarten | Outperform | Reiterates | $20.00 |
| Jan 7, 2026 | Piper Sandler | Kelsey Goodwin | Overweight | Initiates | $22.00 |
| Dec 8, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $20.00 |
| Dec 8, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $25.00 |
| Nov 20, 2025 | Evercore ISI Group | Cory Kasimov | Outperform | Initiates | $25.00 |
| Nov 18, 2025 | Wolfe Research | Kalpit Patel | Peer Perform | Initiates | $N/A |
| Nov 18, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $20.00 |
| Nov 17, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $16.00 |
| Nov 14, 2025 | Oppenheimer | Matthew Biegler | Outperform | Maintains | $15.00 |
| Nov 14, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $23.00 |
| Nov 14, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $19.00 |
| Sep 4, 2025 | Guggenheim | Brad Canino | Buy | Assumes | $18.00 |
| Aug 14, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $17.00 |
| Aug 14, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $19.00 |
Oric Pharmaceuticals Inc. (ORIC) Competitors
The following stocks are similar to ORIC Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ORIC
ORIC Pharmaceuticals
mkt cap
995.75M
Oric Pharmaceuticals Inc. (ORIC) Financial Data
Valuation Metrics
Market Cap
$1.16B
Enterprise Value
$620.14M
P/E Ratio
N/A
PEG Ratio
-5.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.0%
Current Ratio
14.1x
Debt/Equity
1.9x
ROE
-41.3%
ROA
-26.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Oric Pharmaceuticals Inc. (ORIC) Business Model
About Oric Pharmaceuticals Inc.
What They Do
Develops therapies targeting cancer treatment resistance.
Business Model
Oric Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on therapies that address therapeutic resistance in cancer. The company generates revenue through partnerships and collaborations with major pharmaceutical firms, such as Pfizer, Bayer, and Johnson & Johnson, while advancing its product candidates through clinical trials.
Additional Information
Founded in 2014 and based in South San Francisco, California, Oric Pharmaceuticals is actively conducting Phase 1b clinical trials for its lead candidates, rinzimetostat and enozertinib, targeting various cancer types, particularly hormone-dependent cancers and non-small cell lung cancer. The company's innovative approach aims to enhance treatment effectiveness and improve patient outcomes in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
104
CEO
Dr. Jacob M. Chacko M.B.A., M.D.
Country
United States
IPO Year
2020
Website
www.oricpharma.comOric Pharmaceuticals Inc. (ORIC) Latest News & Analysis
Latest News
Quick Summary
Johnson Fistel, PLLP is investigating potential claims for ORIC Pharmaceuticals investors regarding possible losses and compliance with federal securities laws.
Why It Matters
The investigation into ORIC Pharmaceuticals could signal potential legal risks and financial losses, affecting investor confidence and the stock's performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ORIC Pharmaceuticals granted 80,000 stock options and 15,000 restricted stock units to a new employee on April 1, 2026, as part of their compensation package.
Why It Matters
The grant of stock options and restricted stock units indicates a commitment to attract talent and align employee interests with shareholder value, impacting long-term growth potential and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oric stock declined sharply after the company announced that its prostate cancer treatment's effectiveness is similar to that of a competitor's product.
Why It Matters
Oric's stock drop signals reduced competitive advantage in the prostate cancer treatment market, potentially impacting future revenue and investor confidence.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
ORIC Pharmaceuticals discussed Rinzimetostat dose optimization data and the design of a Phase III trial for metastatic prostate cancer in a recent meeting.
Why It Matters
The update on Rinzimetostat's dose optimization and Phase III trial design signals potential advancements in prostate cancer treatment, impacting ORIC's market position and future profitability.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Rinzimetostat 400 mg daily chosen as RP3D with darolutamide for a Phase 3 trial in post-abiraterone mCRPC, expected to begin in 1H 2026.
Why It Matters
The selection of Rinzimetostat as the RP3D for a Phase 3 trial indicates potential for significant advancements in treating mCRPC, impacting future revenue and stock valuation for involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company will hold a conference call and webcast on March 31, 2026, at 4:30 PM ET.
Why It Matters
The scheduled conference call may indicate upcoming financial results or strategic updates, which can impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ORIC Stock
What is Oric Pharmaceuticals Inc.'s (ORIC) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Oric Pharmaceuticals Inc. (ORIC) has a median price target of $22.00. The highest price target is $25.00 and the lowest is $15.00.
Is ORIC stock a good investment in 2026?
According to current analyst ratings, ORIC has 14 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ORIC stock?
Wall Street analysts predict ORIC stock could reach $22.00 in the next 12 months. This represents a 111.9% increase from the current price of $10.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oric Pharmaceuticals Inc.'s business model?
Oric Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on therapies that address therapeutic resistance in cancer. The company generates revenue through partnerships and collaborations with major pharmaceutical firms, such as Pfizer, Bayer, and Johnson & Johnson, while advancing its product candidates through clinical trials.
What is the highest forecasted price for ORIC Oric Pharmaceuticals Inc.?
The highest price target for ORIC is $25.00 from Robert Burns at HC Wainwright & Co., which represents a 140.8% increase from the current price of $10.38.
What is the lowest forecasted price for ORIC Oric Pharmaceuticals Inc.?
The lowest price target for ORIC is $15.00 from Matthew Biegler at Oppenheimer, which represents a 44.5% increase from the current price of $10.38.
What is the overall ORIC consensus from analysts for Oric Pharmaceuticals Inc.?
The overall analyst consensus for ORIC is bullish. Out of 18 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $22.00.
How accurate are ORIC stock price projections?
Stock price projections, including those for Oric Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 3:35 AM UTC